Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 May 17, 2025 07:15AM
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resis Dec 12, 2024 07:00AM
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascula Dec 9, 2024 07:00AM
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates Nov 12, 2024 04:05PM
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® Nov 4, 2024 04:05PM


Nov 4, 2024 07:00AM Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
Oct 29, 2024 07:00AM Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
Oct 28, 2024 07:00AM Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
Sep 3, 2024 07:00AM Fractyl Health to Participate in Upcoming September Investor Conferences
Aug 14, 2024 04:05PM Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Aug 8, 2024 08:00AM Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
Aug 7, 2024 07:00AM Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
Jul 30, 2024 07:02AM Fractyl Health (GUTS) Receives FDA Breakthrough Device Designation for Revita
Jul 30, 2024 07:00AM Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Jun 25, 2024 07:00AM Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Jun 24, 2024 06:00AM Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Jun 23, 2024 01:30PM Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select
May 29, 2024 07:00AM Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 20, 2024 06:00AM Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024 06:00AM Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 13, 2024 04:00PM Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 06:00AM Fractyl Health (GUTS) Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes
May 13, 2024 06:00AM Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
May 8, 2024 06:00AM Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 7, 2024 06:00AM Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Apr 30, 2024 08:38AM Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Apr 2, 2024 08:04AM Fractyl Health (GUTS) Appoints Adrian Kimber as Chief Commercial Officer
Apr 2, 2024 08:00AM Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Ob
Apr 1, 2024 07:00AM Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Apr 1, 2024 06:00AM Fractyl Health (GUTS) Receives FDA IDE Approval for the Revita Remain-1 Study
Apr 1, 2024 06:00AM Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Mar 12, 2024 02:06PM UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semag
Mar 12, 2024 08:39AM Fractyl Health (GUTS) Reports New Results From its Rejuva Platform
Mar 12, 2024 08:38AM Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in
Feb 20, 2024 08:38AM Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials